{"id":"W4283379818","doi":"10.1097/01.hs9.0000846628.17113.b2","title":"P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Adverse effect; Multiple myeloma; Oncology; Clinical endpoint; Expanded access; Clinical trial; Surgery; Gastroenterology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002360241,0.0007745864,0.001689531,0.0002501882,0.0002823179,0.0008826299,0.001004149,0.0006652891,0.002587445],"category_scores_gemma":[0.001187589,0.0004237232,0.001478684,0.0003037062,0.0005503013,0.0008046209,0.0005069135,0.00218034,0.0006538701],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001334728,"about_ca_system_score_gemma":0.001369442,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008120625,"about_ca_topic_score_gemma":0.001783852,"domain_scores_codex":[0.9991435,0.0004254415,0.00006508988,0.0001482155,0.0001294216,0.00008830098],"domain_scores_gemma":[0.9991584,0.0001256081,0.0002444565,0.00007880358,0.00006478393,0.0003280162],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7151961,0.03813776,0.02882105,0.001572605,0.005013992,0.0003446232,0.0003774372,0.003498094,0.05436233,0.0003067972,0.004893039,0.1474762],"study_design_scores_gemma":[0.3563263,0.5593088,0.06239378,0.00008395434,0.002562243,0.0008506504,0.00008995696,0.002321063,0.007340748,0.0002466236,0.008424448,0.0000514833],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941309,0.0023655,0.0003029342,0.0002116708,0.00003634519,0.0006926163,0.001010302,0.00005150955,0.001198078],"genre_scores_gemma":[0.9935833,0.0008745128,0.0009541995,0.0004225183,0.00008840803,0.0007026878,0.00199848,0.00001489622,0.001361058],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002587445,"threshold_uncertainty_score":0.01248229,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01681389065278146,"score_gpt":0.2878218790884212,"score_spread":0.2710079884356397,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}